<DOC>
	<DOCNO>NCT02742909</DOCNO>
	<brief_summary>To evaluate acute effect recombinant human brain natriuretic peptide ( rhBNP ) pulmonary hypertension acute exacerbation chronic pulmonary disease . rhBNP administer continuous infusion 24 hour , pulmonary artery pressure hemodynamic parameter monitor Swan- Ganz catheter .</brief_summary>
	<brief_title>Acute Effects rhBNP Patients With PH Associated With Acute Exacerbation Chronic Pulmonary Disease</brief_title>
	<detailed_description>Pulmonary hypertension ( PH ) descriptive name abnormally elevate pressure pulmonary vasculature , seriously affect quality life survival patient . Currently , effective drug treatment use patient pulmonary hypertension due acute exacerbation lung disease . Recombinant Human Brain Natriuretic Peptide ( rhBNP ) approve 2001 use patient acute heart failure basis study show reduction pulmonary-capillary wedge pressure ( PCWP ) pulmonary arterial pressure ( PAP ) improvement cardiac output ( CO ) . Thus , study design administer rhBNP continuous infusion 24 hour pulmonary hypertension acute exacerbation chronic pulmonary disease monitor Swan- Ganz catheter . Each patient study two occasion ( 6 hour apart ) . One occasion subject receive rhBNP 1.5ug/kg IV bolus follow infusion 0.0075ug/kg/min 24 hour ; occasion subject receive IV placebo bolus follow placebo infusion 24 hour .these administer random order double blind fashion .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>1. age &gt; 18 year old , male female ; 2. acute exacerbation period history chronic respiratory disease ; 3. cardiac ultrasound show pulmonary hypertension ≥50mmHg ; 4. grade II WHO grade heart function ; 5. sign inform consent . 1. pulmonary hypertension associate chronic lung disease ; 2 . Acute severe chronic leave heart failure ; 3. severe respiratory failure receipt noninvasive invasive ventilator therapy ; 4. mPAP≤25mmHg pulmonary capillary wedge pressure ( PCWP ) ≥15mmHg rest assess Swan Ganz catheter ; 5. high risk hypotension ( systolic pressure &lt; 100 mmHg 110 mmHg use intravenous nitroglycerin ) ; 6 . Uncontrolled arterial hypertension ; 7. acute coronary syndrome ; 8 . Severe leave ventricular hypertrophy ; 9 . Congenital acquire valvular myocardial disease ; 10. endstage renal disease receipt renal replacement therapy ; 11. clinically significant anemia ; 12. contraindication vasodilator ; 13. treatment dobutamine ( dose ≥5 μg per kilogram body weight per minute ) ; 14. treatment milrinone levosimendan within previous 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>